| |
 |
Millennium Pharmaceuticals, Inc. Patents |
|
Assignee: Millennium Pharmaceuticals, Inc.
Address: Cambridge, MA
No. of patents: 576
Patents:
| Patent Number |
Title Of Patent |
Date Issued |
| 7611879 |
27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 and 65577 molecules and use |
November 3, 2009 |
| The invention provides isolated nucleic acids molecules, designated 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 and 65577 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 27877, 18080, |
| 7601505 |
Compositions, kits, and methods for identification, assessment, prevention, and therapy of breas |
October 13, 2009 |
| The invention relates to nucleic acid molecules and proteins associated with breast cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast cancers are provided. |
| 7597888 |
Glycoprotein VI and uses thereof |
October 6, 2009 |
| The invention provides isolated nucleic acid molecules and polypeptide molecules that encode glycoprotein VI, a platelet membrane glycoprotein that is involved platelet-collagen interactions. The invention also provides antisense nucleic acid molecules, expression vectors containing |
| 7579168 |
Human Dickkopf-related nucleic acid molecules |
August 25, 2009 |
| Novel Dkk and Dkk-related polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length Dkk and Dkk-related proteins, the invention further provides isolated fusion proteins, antigenic peptides and antibodies. The invention also provides Dkk a |
| 7572784 |
Compounds and methods for inhibiting mitotic progression |
August 11, 2009 |
| This invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer. |
| 7566539 |
Anti-CCR2 antibodies and methods of use therefor |
July 28, 2009 |
| The present invention relates to an antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the |
| 7566450 |
Humanized anti-CCR2 antibodies and methods of use therefor |
July 28, 2009 |
| The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhib |
| 7560461 |
Quinazoline derivatives as kinase inhibitors |
July 14, 2009 |
| The present invention relates to nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention is also related to a method of inhibi |
| 7556938 |
Nucleic acids encoding potassium channel interactors |
July 7, 2009 |
| The invention provides isolated nucleic acids molecules, designated PCIP nucleic acid molecules, which encode proteins that bind potassium channels and modulate potassium channel mediated activities. The invention also provides antisense nucleic acid molecules, recombinant expression |
| 7547766 |
Anti-tango294 antibodies and uses thereof |
June 16, 2009 |
| The invention provides isolated nucleic acids encoding a variety of proteins having diagnostic, preventive, therapeutic, and other uses. These nucleic and proteins are useful for diagnosis, prevention, and therapy of a number of human and other animal disorders. The invention also pr |
| 7547515 |
Methods for detection of the Ob receptor and the diagnosis of body weight disorders, including o |
June 16, 2009 |
| The present invention relates to the discovery, identification and characterization of nucleotides that encode Ob receptor (ObR), a receptor protein that participates in mammalian body weight regulation. The invention encompasses obR nucleotides, host cell expression systems, ObR pro |
| 7544491 |
TANGO 240 nucleic acids and uses thereof |
June 9, 2009 |
| The invention provides isolated nucleic acid molecules, designated TANGO 228 nucleic acid molecules, which encode secreted proteins with homology to the rat MCA-32 protein, isolated nucleic acid molecules, designated TANGO 240 nucleic acid molecules, which encode secreted proteins with |
| 7541365 |
Chemokine receptor antagonists and methods of use therefor |
June 2, 2009 |
| Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: ##STR00001## or physiologically acceptable sal |
| 7534579 |
14273 receptor, a novel G-protein coupled receptor |
May 19, 2009 |
| The present invention relates to a newly identified receptor belonging to the superfamily of G-protein-coupled receptors. The invention also relates to polynucleotides encoding the receptor. The invention further relates to methods using the receptor polypeptides and polynucleotides as |
| 7531526 |
Boronic ester and acid compounds, synthesis and uses |
May 12, 2009 |
| Disclosed herein is a method for reducing the rate of degradation of proteins in an animal, comprising contacting cells of the animal with certain boronic ester and acid compounds. Also disclosed herein are novel boronic ester and acid compounds, their synthesis and uses. |
| 7521470 |
Factor Xa inhibitors |
April 21, 2009 |
| The present invention is directed to compounds represented by Formula I and pharmaceutically acceptable salts, solvates, hydrates, and prodrugs thereof which are inhibitors of Factor Xa. The present invention is also directed to and intermediates used in making such compounds, pharma |
| 7504508 |
PGD2 receptor antagonists for the treatment of inflammatory diseases |
March 17, 2009 |
| Disclosed herein are compounds represented by Structural Formula (I) and (I-A): ##STR00001## Also disclosed is the use of such compounds for inhibiting the G-protein coupled receptor referred to as chemoattractant receptor-homologous molecule expressed on Th2, or simply "CRTH2" for the |
| 7504222 |
Compositions, kits, and methods for identification, assessment, prevention, and therapy of breas |
March 17, 2009 |
| The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast cancers. A variety of newly identified markers are provided, wherein changes in the levels of expression of one or more of the markers is correlated with the |
| 7494793 |
21686, dehydrogenase |
February 24, 2009 |
| The invention provides isolated nucleic acids molecules, designated DHDR nucleic acid molecules, which encode novel DHDR-related dehydrogenase molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing DHDR nucleic acid molecules, |
| 7494775 |
Compositions, kits, and methods for identification, assessment, prevention and therapy of breast |
February 24, 2009 |
| The invention relates to newly discovered nucleic acid molecules and proteins associated with breast or ovarian cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast or ovarian cancers are provided. |
| 7491827 |
Aryl sulfonamides useful as inhibitors of chemokine receptor activity |
February 17, 2009 |
| The present invention provides compounds of general formula I: ##STR00001## or a pharmaceutically acceptable salt thereof, wherein R.sup.1, X, Z, R.sup.2, X.sub.1, Ar, n, R.sup.3 and R.sup.4 are defined generally and in subsets herein. Compounds of the invention are inhibitors of CC |
| 7485431 |
Identification of a family of secreted proteins in vascular endothelium |
February 3, 2009 |
| The invention relates to SCUBE molecules and generally to gene expression in vascular endothelial cells. The invention specifically relates to the discovery of a novel gene family containing the genes and proteins referred to herein as SCUBE1, SCUBE2 and SCUBE3 which can be expressed in |
| 7485308 |
26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 |
February 3, 2009 |
| The invention provides isolated nucleic acids molecules, designated 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 and 8843 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vecto |
| 7485301 |
Methods of treating inflammatory disease using antibodies which bind GPR-9-6 |
February 3, 2009 |
| The invention relates to an antibody or antigen-binding fragment thereof which binds to the CC chemokine receptor GPR-9-6 and blocks the binding of a ligand (e.g., TECK) to the receptor. The invention also relates to a method of identifying agents (molecules, compounds) which can bind to |
| 7482171 |
Angiotensin converting enzyme homolog and uses therefor |
January 27, 2009 |
| The present invention relates to the discovery of novel genes encoding an angiotensin converting enzyme, Angiotensin Converting Enzyme-2 (ACE-2). The invention provides therapeutics, prognostic and diagnostics methods for treating blood pressure related disorders as well as various types |
| 7482147 |
Ubiquitin protease |
January 27, 2009 |
| The invention provides isolated nucleic acids molecules and proteins, designated 27411, 23413, 22438, 23553, 25278, 26212, NARC SC1, NARC 10A, NARC 1, NARC 12, NARC 13, NARC17, NARC 25, NARC 3, NARC 4, NARC 7, NARC 8, NARC 11, NARC 14A, NARC 15, NARC 16, NARC 19, NARC 20, NARC 26, NARC |
| 7473421 |
Humanized anti-CCR2 antibodies and methods of use therefor |
January 6, 2009 |
| The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhib |
| 7470509 |
Compositions and methods for the identification, assessment, prevention and therapy of ovarian c |
December 30, 2008 |
| The present invention is directed to the identification of markers that can be used to determine whether ovarian cancer is sensitive or resistant to a therapeutic agent. In particular, the present invention is directed to the use of certain combinations of markers, wherein the expression |
| 7459530 |
Tango 405 polypeptides and uses thereof |
December 2, 2008 |
| The invention provides isolated nucleic acids encoding a variety of proteins having diagnostic, preventive, therapeutic, and other uses. These nucleic and proteins are useful for diagnosis, prevention, and therapy of a number of human and other animal disorders. The invention also pr |
| 7459448 |
Lactam compounds useful as protein kinase inhibitors |
December 2, 2008 |
| The present invention provides novel compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases. |
| 7452980 |
Compositions and methods for the diagnosis and treatment of immune disorders |
November 18, 2008 |
| The present invention relates to methods and compositions for the treatment and diagnosis of immune disorders, especially T helper lymphocyte-related disorders. In particular, the invention describes a gene known in the art, alternatively, as ST2, T1 and Fit-1, and referred to herein |
| 7452977 |
Antibody to a kinase capable of site-specific phosphorylation of I.kappa.B.alpha. |
November 18, 2008 |
| The present invention relates, in general, to a kinase which in its activated state is capable of site-specific phosphorylation of I.kappa.B.alpha., I.kappa.B.alpha. kinase. In particular, the present invention relates to the purified kinase, antibodies having binding affinity specif |
| 7446181 |
Antibodies that bind human Dickkopf-1 proteins |
November 4, 2008 |
| The invention relates to antibodies and immunologically active portions thereof that selectively bind a human Dickkopf-1 (Dkk-1) or Dkk-1-related polypeptide, and to compositions that contain such antibodies and/or immunologically active portions. |
| 7442775 |
Humanized anti-CCR2 antibodies and methods of use therefor |
October 28, 2008 |
| The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhib |
| 7439029 |
Human 9q polypeptides method |
October 21, 2008 |
| The invention provides isolated nucleic acids molecules, designated PCIP nucleic acid molecules, which encode proteins that bind potassium channels and modulate potassium channel mediated activities. The invention also provides antisense nucleic acid molecules, recombinant expression |
| 7432062 |
Screening methods using B7-H2 molecules, members of the B7 family |
October 7, 2008 |
| Novel B7-like polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length B7-like proteins, the invention further provides isolated B7-like fusion proteins, antigenic peptides, and anti-B7-like antibodies. The invention also provides B7-like |
| 7425424 |
Kinases and uses thereof |
September 16, 2008 |
| Novel kinase polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length kinase proteins, the invention further provides isolated kinase fusion proteins, antigenic peptides, and anti-kinase antibodies. The invention also provides kinase nucl |
| 7423129 |
Antibodies to human eotaxin |
September 9, 2008 |
| The invention relates to isolated and/or recombinant nucleic acids which encode a human chemotactic cytokine designated human eotaxin, and to isolated and/or recombinant human eotaxin proteins or polypeptides, including synthetic polypeptides. The invention further relates to recombi |
| 7411054 |
25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 molecules |
August 12, 2008 |
| The invention provides isolated nucleic acids molecules, designated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 25869, |
| 7410785 |
ACTR-1, a novel human acyltransferase and uses thereof |
August 12, 2008 |
| The invention provides isolated nucleic acid molecules, designated ACTR-1 nucleic acid molecules, which encode novel acyltransferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing ACTR-1 nucleic acid molecules, |
| 7408038 |
Secreted immunomodulatory proteins |
August 5, 2008 |
| The invention concerns cDNA molecules encoding TANGO 191 and TANGO 195, both of which are transmembrane proteins.The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes. Accordingly, in one aspect, this |
| 7407655 |
Method of inhibiting leukocytes with human CXC chemokine receptor 3 antibody |
August 5, 2008 |
| The present invention relates to proteins or polypeptides, referred to herein as isolated and/or recombinant mammalian (e.g., human) IP-10/Mig receptor proteins designated CXC Chemokine Receptor 3 (CXCR3) and variants thereof, including those characterized by selective binding of one |
| 7405275 |
Antibodies which bind human CXCR3 |
July 29, 2008 |
| Antibodies and antigen-binding fragments of antibodies that bind human CXCR3 are disclosed. In preferred embodiments, the antibodies are human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions co |
| 7402657 |
C-C chemokine receptor 3 proteins |
July 22, 2008 |
| The present invention relates to isolated and/or recombinant C-C Chemokine Receptor 3 (CKR-3, CCR3) proteins or polypeptides. |
| 7402410 |
Humanized immunoglobulin reactive with .alpha.4.beta.7 integrin |
July 22, 2008 |
| The present invention relates to isolated nucleic acids encoding humanized immunoglobulins having binding specificity for .alpha.4.beta.7 integrin, isolated nucleic acids encoding a humanized immunoglobulin heavy chain and isolated nucleic acids encoding a humanized light chain having |
| 7385036 |
Human tango 509 polypeptides |
June 10, 2008 |
| The invention provides isolated TANGO 239, TANGO 219, TANGO 232, TANGO 281, A236 (INTERCEPT 236), TANGO 300, TANGO 353, TANGO 393, TANGO 402, TANGO 351 and TANGO 509 nucleic acid molecules and polypeptide molecules. The invention also provides antisense nucleic acid molecules, expression |
| 7381412 |
Anti-TECK antibodies and methods of use therefor |
June 3, 2008 |
| The invention relates to antibodies or antigen-binding fragments thereof which binds the chemokine mammalian TECK and inhibit binding of the chemokine to mammalian GPR-9-6. The invention also relates to host cells that produce such antibodies or antigen-binding fragments, kits compri |
| 7378525 |
CCR8 inhibitors |
May 27, 2008 |
| Disclosed are CCR8 inhibitors represented by Structural Formulas (I): ##STR00001## The variables in Structural Formula (I) are described herein. Also disclosed are methods of treating a subject with a CCR8 mediated condition, especially asthma, by administering one of the disclosed C |
| 7371380 |
Anti-Cark antibodies and uses therefor |
May 13, 2008 |
| The invention provides isolated nucleic acids molecules, designated CARK nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing CARK nucleic acid molecules, host cells into which the expression vectors have been |
| 7361669 |
Compositions and method for inhibiting TGF-.beta. |
April 22, 2008 |
| This invention provides compounds that are inhibitors of the TGF-.beta. signaling pathway. The compounds are represented by formula I: ##STR00001## where A' is N or CH; Ring B is preferably an triazolyl, imidazolyl, or thiazolyl ring; --X-D- is a linker group; and G is an optionally |
|
|
|
